Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otsuka Of Japan Acquires Interpharma Praha Of Czech Republic

This article was originally published in PharmAsia News

Executive Summary

Japan's Otsuka Pharmaceutical says it has acquired the Czech Republic company Interpharma Praha and its expertise in contrast agents for X-rays. The agents would comprise a new product line for Otsuka in a segment of the market that is growing along with the global popularity of CT scans. Otsuka plans to use Interpharma in an effort to expand its presence in Europe, but plans to concentrate on selling the contrast agents in Russia. Interpharma had more than $9.1 million in sales in fiscal 2007. (Click here for more - a subscription may be required

You may also be interested in...



Drug Pricing Policies Attached To Surprise Medical Billing Legislation

Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.

US Government Drug Pricing ‘Negotiation:’ Where We Go From Here

House passes Democratic bill authorizing the federal government to negotiate drug prices in Medicare. While the exercise has sharpened the debate over how prices feed innovation, the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Our table highlights the key provisions of HR 3 and other pending pricing legislation.

Interim Eudamed Scheme: Early SRN Access To Aid Voluntary Actor Registration

The new Eudamed database may be delayed for two years, but the European Commission wants to allow early access to Single Registration Numbers before Eudamed goes live in 2022 to aid voluntary registration in the interim.

UsernamePublicRestriction

Register

SC069403

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel